Close

Clinerion patent for technology underpinning Patient Network Explorer is published

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

When to Bring in Outside Help for FDA Cybersecurity Compliance (and What to Look For)

Medical device cybersecurity has become too important to treat...

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...
- Advertisement -

The new Clinerion patent underpins any medical EHR database infrastructure that incorporates a hybrid model of cloud-and-local server node installations at individual hospitals, as well as any method for search of patient cohort care metrics across such a platform. This allows real-time search at each individual hospital across the entire network at once, returning aggregate metrics from the entire network. This technology forms the basis of Clinerion’s Patient Network Explorer.

System: The patent covers a federated network connecting separate healthcare databases with patient records extracted from hospital information systems. Records containing patient treatment metrics such as diagnoses, medications, treatments, procedures, lab results and vital signs, can be searched disparately to return aggregate cohort results per database. In particular, the patent details the set-up of local hospital servers and de-identification modules that transfer local data into anonymized data servers within the hospital environment, separated from identifiable personal data by a firewall.

Method: The patent includes a methodology for selection and identification of de-identified subjects for clinical study, thereby accelerating cohort search and reducing costs. The patent’s claims include all cases where a patient cohort is selected based on inclusion/exclusion criteria applied to electronic health records (EHRs) at partner hospitals.

The patent builds in data protection, as it incorporates restrictions to data transfer from the local server to outbound connections, while having no inbound ports, thereby preventing hacking of the local server. The patent also describes a firewall, encryption, and/or additional protective components, as well as the use of an anonymization module on patient data before a request may be initiated. The patent further introduces a reverse identification process crucial to clinical research outreach processes, such as patient engagement. Note that ANID, Clinerion’s state-of-the-art technology for unlinked de-identification of patient records, as well as a process for re-identification, is described in a follow-up patent.

In the instance of Clinerion’s Patient Network Explorer, real-time patient searches are enabled across disparate hospital sites, countries, and languages. De-identified EHRs at the partner hospitals may be queried from the Clinerion cloud, returning a cohort count of relevant patients fitting the inclusion/exclusion criteria. This allows:

  • Identification of the patient cohort, as well as extended usages, such as cohort modeling and cohort feasibility, outcomes analysis and chart review feasibility,
  • Analyses of patient reported outcomes, retrospective studies, or any other real-world evidence generation,
  • Diagnostic outreach, fast patient outreach for patient reported outcomes, recruitment to clinical trials based on real-time EHR updates, and secure re-identification routines, and
  • Real-time data metrics across all partner hospitals.

”This patent is the culmination of development work going back many years,” says Dr. Andreas Walter, Clinerion Chief Technology Officer. “Our original aim was to provide huge efficiency savings in patient search for clinical trial recruitment, an area which famously requires high costs and time, using cutting-edge Big Data analytics technologies. We are pleased that the results, in the form of Patient Network Explorer, and all its attending services, now offer real benefits throughout the research timeline.”

“Clinerion’s proprietary technology has always been a solid cornerstone to our business,” says Dr. Barış Erdoğan, Clinerion Chief Executive Officer. “The publication of this patent brings our intellectual property strongly into the light. Having spent many years in healthcare data analytics, we are committed to be a pioneer in the field by bringing in secure, scalable, and trustworthy solutions with the sole aim of creating better patient outcomes.”

“This patent represents the foundation of our venture to solve the hardest problem of simplifying access to real-world data,” says Ulf Claesson, Clinerion Board Member. “How to not only create homogenous views across different geographies, languages, regulations, and coding standards, but also to guarantee full patient privacy. And now we do that across 26 countries around the globe.”

The patent, EP 2015/059415, “PATIENT RECRUITMENT SYSTEM AND PATIENT RECRUITMENT METHOD,” was published in the European Patent Bulletin 2021/30 on July 28th, 2021. The patent was submitted on March 30th, 2014. The related US patent is expected to be published soon.

About Clinerion

Clinerion accelerates clinical research and medical access to treatments for patients. We generate real-world data from our global network of partner hospitals for Real World Evidence analyses. Clinerion‘s Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments.

Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. Researchers gain access to real-time, longitudinal patient data from electronic health records for analysis. We enable pharmaceutical companies, CROs and SMOs to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s Patient Network Explorer also provides a platform for integration of diverse patient data sources into real-world data ecosystems. Clinerion’s proprietary technologies comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

When to Bring in Outside Help for FDA Cybersecurity Compliance (and What to Look For)

Medical device cybersecurity has become too important to treat...

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »